Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 8/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 8/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 8/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 8/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 6/20 | 0.34 |
| ▸ | CCR5 | P51681 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | BPTF | Q12830 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21210559 | 1.00 | CHRNB2 (0.36) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL17694859 | 0.89 | CCR5 (0.36) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL10360894 | 0.86 | HRH3 (0.31) | HRH3 | |
| SCHEMBL10360439 | 0.86 | GNAI3 (0.33) | HRH3 | |
| SCHEMBL27380454 | 0.84 | CHRNB2 (0.43) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL22827192 | 0.84 | CHRNB2 (0.43) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL12250822 | 0.84 | CHRNB2 (0.43) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL19756453 | 0.84 | CHRNB2 (0.43) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL14224176 | 0.84 | CHRNB2 (0.43) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL25646849 | 0.83 | CCR5 (0.41) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4389751-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Kumquat Biosciences Inc. (US) | 2024-06-26 | — | — | EP | disclosed |
| WO-2023172737-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. (US) | 2023-09-14 | — | — | WO | disclosed |
| US-20230265103-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | TME THERAPEUTICS LLC | 2023-08-24 | — | — | US | disclosed |
| US-20220340577-A1 | GCN2 INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2022-10-27 | — | — | US | disclosed |
| US-10988477-B2 | GCN2 inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2021-04-27 | — | — | US | disclosed |
| US-20190233425-A1 | GCN2 INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-08-01 | — | — | US | disclosed |
| US-20150011544-A1 | COMPOUNDS OF ESTROGEN-RELATED RECEPTOR MODULATORS AND THE USES THEREOF | GUANGZHOU INST OF BIOMEDICINE & HEALTH CHINESE ACADEMY OF SCIENCES (CN) | 2015-01-08 | — | — | US | disclosed |
| US-8853221-B2 | Compounds of estrogen-related receptor modulators and the uses thereof | GUANGZHOU INSTITUTE OF BIOMEDICINE & HEALTH, CHINESE ACADEMY OF SCIENCES (CN) | 2014-10-07 | — | — | US | disclosed |
| US-20140296216-A1 | PYRIMIDO[4,5-D]PYRIMIDINYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | GUANGZHOU INSTITUTE OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCES (CN) | 2014-10-02 | — | — | US | disclosed |
| US-8846671-B2 | Heterocyclic alkynyl benzene compounds and medical compositions and uses thereof | GUANGZHOU INSTITUTE OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCES (CN) | 2014-09-30 | — | — | US | disclosed |
| US-20070149553-A1 | Mitotic kinesin inhibitors | ARRINGTON KENNETH L | 2007-06-28 | — | — | US | disclosed |
| US-7235580-B2 | Mitotic kinesin inhibitors | MERCK & CO., INC. (US) | 2007-06-26 | — | — | US | disclosed |
| US-20070142388-A1 | Inhibitors of Akt activity | MERCK SHARP & DOHME CORP. | 2007-06-21 | — | — | US | disclosed |
| US-20070129356-A1 | Mitotic kinesin inhibitors | MERCK SHARP & DOHME CORP. | 2007-06-07 | — | — | US | disclosed |
| US-7223738-B2 | Inhibitors of Akt activity | MERCK & CO., INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-20070082906-A1 | Inhibitors of akt activity | MERCK SHARP & DOHME CORP. | 2007-04-12 | — | — | US | disclosed |
| US-7192949-B2 | Substituted bicyclic pyrimidinones as a mitotic kinesin KSP inhibitors | MERCK & CO., INC. (US) | 2007-03-20 | — | — | US | disclosed |
| US-20070060601-A1 | Mitotic kinesin inhibitors | MERCK SHARP & DOHME CORP. | 2007-03-15 | — | — | US | disclosed |
| US-20070060601-A1 | Mitotic kinesin inhibitors | MERCK SHARP & DOHME CORP. | 2007-03-15 | — | — | US | disclosed |
| US-20070043001-A1 | Inhibitors of akt activity | MERCK SHARP & DOHME CORP. | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265103-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | PIKFYVE, PIK3CD, PIK3R5 | CHRNB2 4013/4885CHRNB4 3980/4885CHRNA3 4159/4885 |
| US-20070149553-A1 | Mitotic kinesin inhibitors | KIF5B, KIF2C, KIF18B | CHRNB2 3787/4885CHRNB4 3883/4885CHRNA3 3851/4885 |
| US-20070043001-A1 | Inhibitors of akt activity | MTMR1, PIK3CA, PLK1 | CHRNB2 4846/4885CHRNB4 4851/4885CHRNA3 4857/4885 |
| US-20070129356-A1 | Mitotic kinesin inhibitors | KIF5B, KIF2C, KIF18B | CHRNB2 3684/4885CHRNB4 3836/4885CHRNA3 3766/4885 |
| US-20150011544-A1 | COMPOUNDS OF ESTROGEN-RELATED RECEPTOR MODULATORS AND THE USES THEREOF | ESRRA, ESRRB, ESRRG | CHRNB2 3729/4885CHRNB4 3276/4885CHRNA3 2550/4885 |
| US-20140296216-A1 | PYRIMIDO[4,5-D]PYRIMIDINYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | EGFR, ERBB2, ERBB4 | CHRNB2 4620/4885CHRNB4 4548/4885CHRNA3 4637/4885 |
| US-20070082906-A1 | Inhibitors of akt activity | AKT2, AKT1, AKT3 | CHRNB2 4836/4885CHRNB4 4849/4885CHRNA3 4835/4885 |
| US-20070060601-A1 | Mitotic kinesin inhibitors | KIF5B, KIF2C, KIF18B | CHRNB2 3576/4885CHRNB4 3767/4885CHRNA3 3448/4885 |
| US-20220340577-A1 | GCN2 INHIBITORS AND USES THEREOF | EIF2AK4, GCN1, GCGR | CHRNB2 4253/4885CHRNB4 4695/4885CHRNA3 4780/4885 |
| US-20070142388-A1 | Inhibitors of Akt activity | AKT2, AKT1, AKT3 | CHRNB2 4848/4885CHRNB4 4866/4885CHRNA3 4835/4885 |
| US-10988477-B2 | GCN2 inhibitors and uses thereof | EIF2AK4, GCN1, EIF2AK1 | CHRNB2 4609/4885CHRNB4 4838/4885CHRNA3 4829/4885 |
| US-20190233425-A1 | GCN2 INHIBITORS AND USES THEREOF | EIF2AK4, GCN1, GCGR | CHRNB2 4253/4885CHRNB4 4695/4885CHRNA3 4780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.